Cue Biopharma - Asset Resilience Ratio
Cue Biopharma (CUE) has an Asset Resilience Ratio of 22.03% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Cue Biopharma's Asset Resilience Ratio has changed over time. Check how strategically is Cue Biopharma's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Cue Biopharma's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Cue Biopharma.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $6.97 Million | 22.03% |
| Total Liquid Assets | $6.97 Million | 22.03% |
Asset Resilience Insights
- Good Liquidity Position: Cue Biopharma maintains a healthy 22.03% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Cue Biopharma Industry Peers by Asset Resilience Ratio
Compare Cue Biopharma's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Cue Biopharma (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Cue Biopharma.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 2.89% | $929.00K | $32.19 Million | -- |
| 2023-12-31 | 0.00% | $0.00 | $61.53 Million | -- |
| 2022-12-31 | 27.03% | $24.68 Million | $91.28 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $83.40 Million | -- |
| 2020-12-31 | 10.05% | $10.00 Million | $99.53 Million | -11.07pp |
| 2019-12-31 | 21.12% | $15.12 Million | $71.61 Million | -19.47pp |
| 2018-12-31 | 40.59% | $18.41 Million | $45.36 Million | +40.51pp |
| 2017-12-31 | 0.07% | $50.07K | $66.95 Million | -0.23pp |
| 2016-12-31 | 0.31% | $50.03K | $16.28 Million | -0.38pp |
| 2015-12-31 | 0.68% | $50.00K | $7.31 Million | -- |
About Cue Biopharma
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States. Its lead drug product candidate is the CUE-401, a novel approach to induce and expand antigen specific Tregs for regulating disease causing autoreactive Teff cells which is in preclinical tria… Read more